Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Forecast: Breaking Down The Numbers Behind Future Expansion

Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Revenue Growth On Track For A 16.2% CAGR Through 2030

The market size for glucagon-like peptide (glp)-1 agonists weight loss drugs has experienced rapid expansion in recent years. Projections indicate it will expand from $15.5 billion in 2025 to $18.02 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.3%. This historical growth is largely due to factors such as rising obesity prevalence, diabetes drug innovation, the burden of lifestyle diseases, early glp-1 diabetes use, and various healthcare awareness campaigns.

The market for glucagon-like peptide (glp)-1 agonists weight loss drugs is projected to experience swift expansion over the coming years, reaching a valuation of $32.87 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 16.2%. This anticipated growth during the forecast period is primarily driven by factors such as the approval of novel glp-1 medications, the broadening of obesity clinic networks, enhanced insurance coverage, a greater emphasis on sustained weight management, and increasing worldwide obesity prevalence. Key trends identified for the forecast period encompass a surging demand for drug-based weight management solutions, an uptick in the utilization of injectable weight loss medications, the expanding application of glp-1 therapies for conditions other than diabetes, the enlargement of obesity treatment initiatives, and better patient compliance with extended therapeutic regimens.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=70080861&type=smp&name=Glucagon-Like%20Peptide%20%28GLP%29-1%20Agonists%20Weight%20Loss%20Drugs%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Growth Momentum: What Factors Are Shaping Demand?

The increasing incidence of obesity is anticipated to drive the expansion of the glucagon-like peptide (GLP)-1 agonist weight loss drugs market in the future. This medical condition is defined by the dangerous accumulation of excess body fat, posing significant health risks. The rise in obesity rates primarily stems from poor dietary choices, including higher consumption of fast food and sugary beverages, which often lack essential nutrients and balance. As a growing number of individuals are affected by obesity and its associated health issues, the demand for effective treatment options is escalating. This, in turn, boosts the adoption of glucagon-like peptide (GLP)-1 agonist weight loss drugs due to their demonstrated efficacy in promoting weight loss and improving metabolic well-being. For instance, data released in May 2025 by the Office for Health Improvement and Disparities, a UK government entity, revealed that from 2023 to 2024, approximately 64.5% of adults aged 18 and over in England were classified as overweight or obese, marking an increase from 64.0% observed in the period of 2022 to 2023. Consequently, the expanding prevalence of obesity is a key factor propelling the growth of the glucagon-like peptide (GLP)-1 agonist weight loss drugs market.

Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Segments: Where Is Growth Concentrated?

The glucagon-like peptide (glp)-1 agonists weight loss drugs market covered in this report is segmented –

1) By Drugs: Semaglutide, Liraglutide, Tirzepatide, Other Drugs

2) By Route of Administration: Parenteral, Oral

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Pharmacies

Subsegments:

1) By Semaglutide: Ozempic, Wegovy, Rybelsus

2) By Liraglutide: Saxenda, Victoza

3) By Tirzepatide: Mounjaro, Zepbound

4) By Other Drugs: Exenatide, Dulaglutide, Albiglutide, Efpeglenatide

Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Trends: What’s Defining The Industry’s Next Phase?

Leading companies in the glucagon-like peptide (GLP)-1 agonist weight loss drugs market are creating innovative obesity treatment solutions designed to boost their efficacy and improve patient outcomes. These obesity treatment solutions are therapies engineered to mimic the GLP-1 hormone, thereby managing appetite, increasing feelings of fullness, and facilitating weight reduction. Such medications aid in controlling obesity by refining metabolic function and fostering sustained weight management. For example, in November 2023, Eli Lilly and Company, a US-based pharmaceutical company, obtained US Food and Drug Administration approval for Zepbound. This drug is intended for chronic weight management in adults with obesity or those who are overweight and have associated health conditions like type 2 diabetes or sleep apnea. Zepbound operates by activating both GIP and GLP-1 hormone receptors to suppress appetite and enhance metabolic function.

Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Key Participants And Competitive Landscape

Major companies operating in the glucagon-like peptide (glp)-1 agonists weight loss drugs market are Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Merck & Co Inc, Boehringer Ingelheim, Hanmi Pharmaceutical, Jiangsu Hengrui Medicine Co Ltd, Zealand Pharma A/S, I-Mab Biopharma Shanghai Co Ltd, Altimmune Inc, BioAge Labs, Innovent Biologics Inc, Viking Therapeutics Inc, Structure Therapeutics Inc, Regor Therapeutics Inc, TheracosBio LLC, Oramed Pharmaceuticals, Amgen Inc, Roche Holding AG, Teva Pharmaceutical Industries Ltd

View The Full Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report:

https://thebusinessresearchcompany.com/report/glucagon-like-peptide-glp-1-agonists-weight-loss-drugs-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Largest Region: Which Geography Holds The Biggest Share?

North America was the largest region in the glucagon-like peptide (GLP) -1 agonists weight loss drugs market in 2025. The regions covered in the glucagon-like peptide (glp)-1 agonists weight loss drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model